Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysis.

Abstract : BACKGROUND: The new 2010 World Health Organization (WHO) HIV treatment guidelines recommend earlier antiretroviral therapy (ART) initiation (CD4<350 cells/µl instead of CD4<200 cells/µl), multiple sequential ART regimens, and replacement of first-line stavudine with tenofovir. This paper considers what to do first in resource-limited settings where immediate implementation of all of the WHO recommendations is not feasible. METHODS AND FINDINGS: We use a mathematical model and local input data to project clinical and economic outcomes in a South African HIV-infected cohort (mean age = 32.8 y, mean CD4 = 375/µl). For the reference strategy, we assume that all patients initiate stavudine-based ART with WHO stage III/IV disease and receive one line of ART (stavudine/WHO/one-line). We rank-in survival, cost-effectiveness, and equity terms-all 12 possible combinations of the following: (1) stavudine replacement with tenofovir, (2) ART initiation (by WHO stage, CD4<200 cells/µl, or CD4<350 cells/µl), and (3) one or two regimens, or lines, of available ART. Projected life expectancy for the reference strategy is 99.0 mo. Considering each of the guideline components separately, 5-y survival is maximized with ART initiation at CD4<350 cells/µl (stavudine/<350/µl/one-line, 87% survival) compared with stavudine/WHO/two-lines (66%) and tenofovir/WHO/one-line (66%). The greatest life expectancies are achieved via the following stepwise programmatic additions: stavudine/<350/µl/one-line (124.3 mo), stavudine/<350/µl/two-lines (177.6 mo), and tenofovir/<350/µl/two-lines (193.6 mo). Three program combinations are economically efficient: stavudine/<350/µl/one-line (cost-effectiveness ratio, US$610/years of life saved [YLS]), tenofovir/<350/µl/one-line (US$1,140/YLS), and tenofovir/<350/µl/two-lines (US$2,370/YLS). CONCLUSIONS: In settings where immediate implementation of all of the new WHO treatment guidelines is not feasible, ART initiation at CD4<350 cells/µl provides the greatest short- and long-term survival advantage and is highly cost-effective.
Type de document :
Article dans une revue
PLoS Medicine, Public Library of Science, 2010, 7 (12), pp.e1000382. 〈10.1371/journal.pmed.1000382〉
Liste complète des métadonnées

Littérature citée [30 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-00702692
Contributeur : Evelyne Mouillet <>
Soumis le : jeudi 31 mai 2012 - 10:14:10
Dernière modification le : lundi 8 octobre 2018 - 21:16:03
Document(s) archivé(s) le : samedi 1 septembre 2012 - 02:22:28

Fichier

journal.pmed.1000382.pdf
Fichiers éditeurs autorisés sur une archive ouverte

Identifiants

Collections

Citation

Rochelle Walensky, Robin Wood, Andrea Ciaranello, David Paltiel, Sarah Lorenzana, et al.. Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysis.. PLoS Medicine, Public Library of Science, 2010, 7 (12), pp.e1000382. 〈10.1371/journal.pmed.1000382〉. 〈inserm-00702692〉

Partager

Métriques

Consultations de la notice

130

Téléchargements de fichiers

99